Xiaoke Pill lowered hypoglycemia risk with similar HbA1c control

Evidence Suggest

• In the drug-naive group, Xiaoke Pill lowered the odds of any hypoglycemia by 38% and mild hypoglycemia by 41% versus glibenclamide.
• In the metformin group, Xiaoke Pill lowered the annual hypoglycemia rate by 62% compared with glibenclamide.
• HbA1c fell by 0.70% with Xiaoke Pill and 0.66% with glibenclamide in the drug-naive group, and by 0.45% versus 0.59% in the metformin group.
• No serious adverse event was reported during the 48-week trial.

Who this applies to

These findings apply most directly to adults aged 21 to 70 with type 2 diabetes, poor glycemic control, and either no prior glucose-lowering drugs or stable metformin use. The results are less certain for non-Chinese populations, people with advanced complications, or those using insulin or other modern drug combinations.

Keep in Mind

Xiaoke Pill was compared with glibenclamide alone, not with newer diabetes treatments. The trial supports similar glucose lowering and fewer hypoglycemia episodes, but it does not prove that the herbal components improve long-term complications. Treatment decisions should still consider access, safety monitoring, and whether sulfonylurea therapy is appropriate in the first place.

Between the Lines

• All participants were treated in China, so generalizability may be limited.
• The study used an active comparator, not a placebo-only herbal control.
• Xiaoke Pill already contains glibenclamide, so the herbal effect cannot be isolated fully.
• Some secondary outcomes were subgroup-based or not fully detailed in the main text.